Abrysvo Pfizer RSV bivalent
Selected indexed studies
- Nirsevimab and Maternal Respiratory Syncytial Virus Vaccine Recommendations for the Pediatric Population. (Pediatr Ann, 2025) [PMID:40305635]
- Assessing the risk of Guillain-Barré syndrome in older adults after bivalent RSV pre-F vaccination in England. (Nat Commun, 2025) [PMID:41381510]
- Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment. (Obstet Gynecol Surv, 2024) [PMID:39437376]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Nirsevimab and Maternal Respiratory Syncytial Virus Vaccine Recommendations for the Pediatric Population. (2025) pubmed
- Assessing the risk of Guillain-Barré syndrome in older adults after bivalent RSV pre-F vaccination in England. (2025) pubmed
- Provider Guidance for the Prevention of Respiratory Syncytial Virus in Infants: Maternal Vaccination Versus Infant Monoclonal Antibody Treatment. (2024) pubmed
- Favorable Nonclinical Safety Profile of RSVpreF Bivalent Vaccine in Rats and Rabbits. (2024) pubmed
- Maternal RSV vaccination generates high-affinity antibodies that efficiently transfer to infants, providing enhanced passive immunity. (2026) pubmed
- Bivalent RSV prefusion F vaccination elicits effective neutralization of contemporary and monoclonal antibody-resistant RSV strains. (2026) pubmed
- Respiratory Syncytial Virus Prefusion F Subunit Vaccine: First Approval of a Maternal Vaccine to Protect Infants. (2023) pubmed